BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Equities researchers at Leerink Swann upped their FY2018 EPS estimates for BioMarin Pharmaceutical in a research report issued on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the biotechnology company will post earnings per share of $0.48 for the year, up from their previous forecast of $0.46. Leerink Swann has a “Buy” rating on the stock. Leerink Swann also issued estimates for BioMarin Pharmaceutical’s FY2020 earnings at $1.54 EPS.

Several other research analysts also recently weighed in on the stock. Stifel Nicolaus restated a “buy” rating and set a $107.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday. Cowen and Company restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Friday. Deutsche Bank AG restated a “buy” rating and set a $119.00 price target (up previously from $118.00) on shares of BioMarin Pharmaceutical in a research report on Thursday. UBS AG restated a “neutral” rating and set a $93.00 price target (up previously from $92.00) on shares of BioMarin Pharmaceutical in a research report on Thursday. Finally, Sanford C. Bernstein began coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, July 27th. They set a “market perform” rating and a $89.00 price target for the company. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the company’s stock. BioMarin Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $110.20.

WARNING: “Leerink Swann Weighs in on BioMarin Pharmaceutical Inc.’s FY2018 Earnings (NASDAQ:BMRN)” was originally published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/05/leerink-swann-weighs-in-on-biomarin-pharmaceutical-inc-s-fy2018-earnings-nasdaqbmrn.html.

Shares of BioMarin Pharmaceutical (BMRN) traded up 0.20% on Friday, hitting $89.70. The stock had a trading volume of 897,663 shares. BioMarin Pharmaceutical has a 12 month low of $78.42 and a 12 month high of $102.49. The firm’s market cap is $15.72 billion. The firm’s 50-day moving average price is $90.43 and its 200 day moving average price is $90.03.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.01. The firm had revenue of $317.50 million during the quarter, compared to analyst estimates of $311.41 million. BioMarin Pharmaceutical had a negative return on equity of 5.77% and a negative net margin of 15.54%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the business posted ($2.61) earnings per share.

In other news, SVP Brian Mueller sold 7,482 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The shares were sold at an average price of $91.87, for a total value of $687,371.34. Following the transaction, the senior vice president now directly owns 18,350 shares in the company, valued at approximately $1,685,814.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jean Jacques Bienaime sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, May 8th. The stock was sold at an average price of $96.09, for a total transaction of $960,900.00. Following the completion of the transaction, the chief executive officer now owns 238,496 shares in the company, valued at $22,917,080.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 79,222 shares of company stock worth $7,307,860. Company insiders own 2.50% of the company’s stock.

Several institutional investors have recently modified their holdings of BMRN. State Board of Administration of Florida Retirement System raised its position in shares of BioMarin Pharmaceutical by 1.0% in the second quarter. State Board of Administration of Florida Retirement System now owns 254,166 shares of the biotechnology company’s stock valued at $23,083,000 after buying an additional 2,521 shares in the last quarter. Jennison Associates LLC raised its position in shares of BioMarin Pharmaceutical by 33.8% in the second quarter. Jennison Associates LLC now owns 13,242,773 shares of the biotechnology company’s stock valued at $1,202,709,000 after buying an additional 3,348,168 shares in the last quarter. Nippon Life Insurance Co. raised its position in shares of BioMarin Pharmaceutical by 43.5% in the second quarter. Nippon Life Insurance Co. now owns 11,828 shares of the biotechnology company’s stock valued at $1,074,000 after buying an additional 3,583 shares in the last quarter. Chartwell Investment Partners LLC raised its position in shares of BioMarin Pharmaceutical by 2.6% in the second quarter. Chartwell Investment Partners LLC now owns 12,803 shares of the biotechnology company’s stock valued at $1,163,000 after buying an additional 325 shares in the last quarter. Finally, KBC Group NV raised its position in shares of BioMarin Pharmaceutical by 18.6% in the second quarter. KBC Group NV now owns 337,608 shares of the biotechnology company’s stock valued at $30,662,000 after buying an additional 52,847 shares in the last quarter. Hedge funds and other institutional investors own 96.77% of the company’s stock.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.